Advaxis Inc Cmn Stk (ADXS) 8.67 $ADXS Advaxis to Present

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 5:10 PM

Advaxis Inc Cmn Stk (ADXS) 8.67 $ADXS

Advaxis to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Fri Jul 08, 7:00AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at Cantor Fitzgerald's 2nd Annual Healthcare Conference being held July 12-13, 2016 in New York, N.Y.
ADXS: 8.67 (+0.06)

Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 8.67 (+0.06)

Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 8.67 (+0.06)

Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 8.67 (+0.06)

UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.67 (+0.06)

Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.67 (+0.06)

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 8.67 (+0.06)

Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 8.67 (+0.06)

AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 8.67 (+0.06)

Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 8.67 (+0.06)

Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 8.67 (+0.06)

Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 8.67 (+0.06), MRK: 59.34 (-0.01)

Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 8.67 (+0.06)

Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 8.67 (+0.06)

UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 7:08AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.67 (+0.06)

Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.67 (+0.06)

Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
GlobeNewswire - Mon Mar 21, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was published online March 18, 2016 in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
ADXS: 8.67 (+0.06)

Advaxis to Present at Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it is scheduled to present on Wednesday, March 16, 2016 at 4:20 p.m. EDT at the 2016 Barclays Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida.
ADXS: 8.67 (+0.06)

Advaxis Elects Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors
GlobeNewswire - Fri Mar 11, 8:05AM CST
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Gregory Mayes, Executive Vice President and Chief Operating Officer, has been elected to the Company's Board of Directors.
ADXS: 8.67 (+0.06)

Advaxis Truly Personalized Cancer Immunotherapy Moves Forward With Signing of an Exclusive Supply Agreement With Synthetic Genomics for Synthetic DNA
GlobeNewswire - Wed Mar 09, 6:05AM CST
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, and SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI), today announced that the companies have entered into a five-year exclusive supply agreement. Under the terms of the agreement, SGI-DNA will manufacture for Advaxis synthetic DNA which will be used in Advaxis' personalized Listeria monocytogenes (Lm)-based immunotherapy, known as MINE(TM) (My Immunotherapy Neo-Epitopes).
ADXS: 8.67 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...